

GLOBAL NEWS

FDA APPROVES NEW COMBINATION INJECTION FOR SEDATION AND PAIN RELIEF IN DOGS

DVM360, April 5th 2022



The drug product is a balanced combination of medetomidine and vatinoxan. Officials with the FDA have approved medetomidine and vatinoxan hydrochlorides injection for use as a sedative and analgesic in dogs, while undergoing certain clinical examination and procedures, and minor surgical procedures. This is the first approval of vatinoxan by the FDA. The drug product is a balanced combination of medetomidine, an alpha2-adrenoceptor agonist, and vatinoxan, an alpha2-adrenoceptor antagonist. Medetomidine, a sedative with analgesic properties that has already been approved for use in dogs, can cause a decrease in an animal's heart rate and can increase the chance of arrhythmias, which can be significant in some dogs. Vatinoxan reduces the negative cardiovascular effects of medetomidine by keeping the heart rate closer to the normal range, thereby improving cardiovascular function, and improving the safety profile of medetomidine while the dog is sedated. The combination injection is the first sedative to possess this unique combination of active pharmaceutical ingredients and effects, according to an organizational press release.

REGENERATIVE MEDICINE 2.0: EXTRACELLULAR VESICLE-BASED THERAPEUTICS FOR MUSCULOSKELETAL TISSUE REGENERATION

AVMA, April 2022

In recent years, extracellular vesicles (EVs) have emerged as prominent mediators of the homeostasis, repair, and regeneration of musculoskeletal tissues including bone, skeletal muscle, and cartilage. Accordingly, the therapeutic potential of EVs for regenerative medicine applications has not gone unnoticed. The use of EVs for the treatment of musculoskeletal injury and disease in veterinary species is a nascent but rapidly expanding area of research. Recent studies in this area have demonstrated the safety and feasibility of EV products in dogs and horses. While early clinical responses to EV-based therapeutics in companion animals have been favorable, more rigorously designed, sufficiently powered, and placebo-controlled clinical trials are required to fully elucidate the clinical benefits and best-use scenarios for EV therapeutics in veterinary medicine. Additionally, clinical translation of EV-based therapeutics will require Good Manufacturing Practice-compliant methods to scale up and purify EV products. Despite these challenges, EVs hold great promise in the regenerative medicine landscape, particularly in the treatment of musculoskeletal injury and disease in companion animals.

SURVEY SHINES LIGHT ON LACK OF COGNITIVE DYSFUNCTION AWARENESS

Vet Times, April 5th 2022

More than a quarter of all cat and dog owners are unaware their pet can develop cognitive dysfunction syndrome. A survey commissioned for Vets4Pets as part of a wider campaign to raise consumer awareness of the condition and improve early detection also found half of respondents would not be confident identifying early indicators of it, which include confusion, anxiety, restlessness and a decreased desire to play. A total of 62% said they would put significant behavioural changes in their pet down to getting old. Three in five of the 2,000 survey respondents admitted they would find it difficult to understand the signs for when it was time to take their pet to the vet.

**Bark Out
= Loud =**

NEW RVC STUDY REVEALS CONSEQUENCES OF 2020 PANDEMIC RESTRICTIONS ON PUPPIES



A study by the Royal Veterinary College (RVC) has revealed that puppies purchased during the pandemic in 2020, in comparison to pre-pandemic in 2019, were more likely to have been 'designer crossbreeds', for example a Cockapoo or Cavapoo, instead of Kennel Club registered purebred dogs. These findings are important to improve advice to the public on responsible purchasing that prioritises puppy welfare, as well as how best to manage puppy behavioural issues that may have arisen because of lockdown restrictions. The Pandemic Puppies study, funded by the BVA Animal Welfare Foundation, is the largest of its kind - compiling data from more than 5,500 UK owners using an online survey. It explored the early socialisation, health and behaviour of 'pandemic puppies' purchased in 2020 compared to 2019 puppies. Because of lockdown restrictions, there were still some concerns such as 2020 'pandemic puppies' being less likely than 2019 puppies to attend puppy training classes or to have experienced visitors to their homes. The RVC's researchers believe these differences between 2019 and 2020 puppies could potentially lead to the development of future behavioural problems in some pandemic puppies. For example, pandemic puppies may experience stranger-related fear and anxiety (due to the limited prior exposure to visitors to their home) and other behavioural problems related to insufficient socialisation. As a result, enhanced support is likely needed from the veterinary profession, particularly those specialising in animal behaviour, to help owners of 'pandemic puppies' and their effects, according to an organizational press release.

CALMING & ANTI - ANXIETY SUPPLEMENT



Presentation:
2gm sachet

Dose/Directions For Use

Weight	For dogs	For cats
Up to 11kg	1/4 sachet	1/8 sachet
11-22 kg	1/2 sachet	-
22kg & above	1 sachet	-

To be administered an hour before any stressful event. Twice a day in case of chronic anxiety

Stay connected with

[facebook.com/vivaldisanimalhealth](https://www.facebook.com/vivaldisanimalhealth) | [instagram.com/vivaldisanimalhealth](https://www.instagram.com/vivaldisanimalhealth) | [linkedin.com/company/vivaldisanimalhealth](https://www.linkedin.com/company/vivaldisanimalhealth)

VIVALDIS
Animal Health

Vivaldis Health & Foods Pvt. Ltd.

Office No. 803/804, Clover Hills Plaza, NIBM Road, Pune- 411048, Maharashtra, India.

Help-line No.: +91 7767922244 | Email : info@vivaldis.co.in | Website : www.vivaldis.co.in

1. <https://rb.gy/cg5rkb> | 2. <https://rb.gy/fexb7w> | 3. <https://rb.gy/hsc3q9> | 4. <https://rb.gy/btjyrc>